Epiomic Epidemiology Series: Frontotemporal Lobe Dementia Forecast in 19 Major Markets 2018–2028

June 2018 | 70 pages | ID: E8D3D71E049EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Frontotemporal Lobe Dementia in 19 Major Markets

Frontotemporal lobe dementia (FTD) is a progressive degenerative disorder characterised by degeneration and atrophy of the frontal and anterior temporal lobes. It is the second most common neurodegenerative disorder resulting in dementia in the under 65's and a limited life expectancy. This report provides the current prevalent population for FTD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides a breakdown of the sub-group classifications of the disease, disease origin and tau protein mutations in the FTD patient population. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of FTD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for FTD include:

• Dementia and cognitive disorders
• Speech and semantic problems
• Limb/muscle weakness and rigidity
• Behavioural disorders
• Appetite changes

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

REASON TO BUY

• Able to quantify patient populations in global FTD market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of FTD and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on FTD prevalent population.
• Examination of the prevalence for different causative protein mutations in FTD.
• Identify sub-populations within FTD which require treatment.
• Gain an understanding of the specific markets that have the largest number of FTD patients.

Contents

INTRODUCTION
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS/FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR FTD
FEATURES OF FTD PATIENTS
CLASSIFICATION
GENETIC BACKGROUND
NEUROLOGICAL/BEHAVIOURAL SYMPTOMS
COMORBIDITIES OF FTD PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER BLACK SWAN SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Prevalence of FTD, total (000s)
Table 2. Prevalence of FTD, males (000s)
Table 3. Prevalence of FTD, females (000s)
Table 4. Patients with FTD by sub-group classification/clinical syndrome, total (000s)
Table 5. Patients with FTD by origin/form, total (000s)
Table 7. Patients with FTD by severity (stage), total (000s)
Table 6. Patients with FTD by presence and type of Tau mutation, total (000s)
Table 8. FTD patients with PGRN mutation, total (000s)
Table 9. Tau-negative ubiquitin-positive FTD (FTD-U) patients, total (000s)
Table 10. FTD patients with disinhibition in NPI, total (000s)
Table 11. FTD patients with apathy in NPI, total (000s)
Table 12. FTD patients with agitation in NPI, total (000s)
Table 13. FTD patients with anxiety in NPI, total (000s)
Table 14. FTD patients with amyotrophic lateral sclerosis, total (000s)
Table 15. FTD patients with Alzheimer's disease, total (000s)
Table 16. Abbreviations and acronyms used in the report
Table 17. USA prevalence of FTD by 5-yr age cohort, males (000s)
Table 18. USA prevalence of FTD by 5-yr age cohort, females (000s)
Table 19. Canada prevalence of FTD by 5-yr age cohort, males (000s)
Table 20. Canada prevalence of FTD by 5-yr age cohort, females (000s)
Table 21. France prevalence of FTD by 5-yr age cohort, males (000s)
Table 22. France prevalence of FTD by 5-yr age cohort, females (000s)
Table 23. Germany prevalence of FTD by 5-yr age cohort, males (000s)
Table 24. Germany prevalence of FTD by 5-yr age cohort, females (000s)
Table 25. Italy prevalence of FTD by 5-yr age cohort, males (000s)
Table 26. Italy prevalence of FTD by 5-yr age cohort, females (000s)
Table 27. Spain prevalence of FTD by 5-yr age cohort, males (000s)
Table 28. Spain prevalence of FTD by 5-yr age cohort, females (000s)
Table 29. UK prevalence of FTD by 5-yr age cohort, males (000s)
Table 30. UK prevalence of FTD by 5-yr age cohort, females (000s)
Table 31. Poland prevalence of FTD by 5-yr age cohort, males (000s)
Table 32. Poland prevalence of FTD by 5-yr age cohort, females (000s)
Table 33. Netherlands prevalence of FTD by 5-yr age cohort, males (000s)
Table 34. Netherlands prevalence of FTD by 5-yr age cohort, females (000s)
Table 35. Russia prevalence of FTD by 5-yr age cohort, males (000s)
Table 36. Russia prevalence of FTD by 5-yr age cohort, females (000s)
Table 37. Turkey prevalence of FTD by 5-yr age cohort, males (000s)
Table 38. Turkey prevalence of FTD by 5-yr age cohort, females (000s)
Table 39. Japan prevalence of FTD by 5-yr age cohort, males (000s)
Table 40. Japan prevalence of FTD by 5-yr age cohort, females (000s)
Table 41. China prevalence of FTD by 5-yr age cohort, males (000s)
Table 42. China prevalence of FTD by 5-yr age cohort, females (000s)
Table 43. South Korea prevalence of FTD by 5-yr age cohort, males (000s)
Table 44. South Korea prevalence of FTD by 5-yr age cohort, females (000s)
Table 45. India prevalence of FTD by 5-yr age cohort, males (000s)
Table 46. India prevalence of FTD by 5-yr age cohort, females (000s)
Table 47. Australia prevalence of FTD by 5-yr age cohort, males (000s)
Table 48. Australia prevalence of FTD by 5-yr age cohort, females (000s)
Table 49. Brazil prevalence of FTD by 5-yr age cohort, males (000s)
Table 50. Brazil prevalence of FTD by 5-yr age cohort, females (000s)
Table 51. Mexico prevalence of FTD by 5-yr age cohort, males (000s)
Table 52. Mexico prevalence of FTD by 5-yr age cohort, females (000s)
Table 53. Argentina prevalence of FTD by 5-yr age cohort, males (000s)
Table 54. Argentina prevalence of FTD by 5-yr age cohort, females (000s)